Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $23
Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.
Last updated: 2026-11-19 07:54:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Oric Pharmaceuticals, Inc. (ORIC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.66, with a market capitalization of $831.45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.23 to $14.68. This page covers its latest market performance, valuation, price trends and company information.
$831.45M | |
$7.91 | |
$8.27 | |
$7.54 | |
$8.00 | |
1.07M | |
1.59M | |
-- | |
$14.68 | |
$7.23 | |
-- | |
2026-06-30 |
Oric Pharmaceuticals, Inc. (ORIC) last closed at $7.66 as of 2026-11-19 00:31:00, down 4.63% ($0.37) from the previous close of $8.00.
During the latest regular trading session, ORIC traded between $7.54 and $8.27, with a volume of 1.07M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Oric Pharmaceuticals, Inc. (ORIC) moved from $8.91 to $7.66, representing a decline of 14.04% ($1.25).
The stock traded between $7.50 and $9.45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.22 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.8%
ORIC is currently trading at $7.66, placing it 5.8% of the way from its 52-week low of $7.23 to its 52-week high of $14.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 119 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Oric Pharmaceuticals, Inc. and ORIC stock.
Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 33.33 percent decrease over losses of $(0.33) per
Eligible investors can buy real shares of Oric Pharmaceuticals, Inc. (ORIC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ORIC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ORIC shares and USD.
ORIC Shares to USD
1.00 ORIC shares = 7.659 USD
Calculations are estimates based on the latest available price and are for reference only.